Effectiveness of oxibendazole against benzimidazole-resistant strongyles in horses

Twenty-eight horses with a residual burden of strongyle eggs in the faces after treatment with mebendazole (MBZ) paste were treated with a suspension of either MBZ or oxibendazole (OBZ). Fecal samples were collected before and 14 days after these treatments. The number of strongyle eggs/g (epg) of feces for each horse was estimated using the Cornell-McMaster dilution and the Cornell-Wisconsin double centrifugation procedures. The epg for each horse was transformed using log (× + 1) and in an analysis of variance of the reduction in egg count for each horse on the logarithmic scale, there was a highly significant difference between the treatments. The mean epg was increased in the MBZ-treated horses and reduced in the OBZ-treated horses, but the reduction was only by 82% with an upper confidence limit of 89%. Subsequently, the horses were retreated with MBZ and OBZ suspensions without significant reduction in the mean epg for OBZ-treated horses.     

Experimental chemotherapy in horses infected with benzimidazole-resistant small strongyles

The presence of benzimidazole-resistant strains of equine small strongyles was confirmed in horses at two properties in north west England by a series of faecal egg counts and larval cultures after treatment with mebendazole. A trail formulation of mebendazole in combination with piperazine citrate gave greater reductions in faecal egg counts than mebendazole alone but was much less effective than pyrantel embonate or dichlorvos.     

In vitro field screening for anthelmintic resistance in strongyles of sheep and horses

Simplified in vitro field methods are described for the detection and assay of benzimidazole-resistance in sheep trichostrongylids and horse strongyles. Worm eggs are recovered from fresh faeces, within 1 hour of collection, by flotation in sugar solution. The separated eggs are then incubated for 20–24 hours at 27–30° C in solutions of thiabendazole in distilled water ranging from 0.1 to 1.1 p.p.m. for sheep trichostrongylids and from 0.05 to 0.5 p.p.m. for horse strongyles. Under controlled conditions, eggs from thiabendazole-susceptible individuals of both sheep and horse nematodes rarely hatch at thiabendazole concentrations of 0.1 p.p.m. Eggs from resistant individuals will hatch at 0.1 p.p.m. and above. Semi-quantitative estimates of the level of resistance can be determined by measuring the % egg-hatch at varying concentrations of thiabendazole. A field method for selecting test animals with low egg-counts, and an in vitro method for the culture of eggs or first-stage larvae to third stage for identification are described.     

Efficacy of moxidectin and other anthelmintics against small strongyles in horses

Objective To compare the efficacy of moxidectin to ivermectin, oxibendazole and morantel against some gastrointestinal nematodes in horses.
Design Faecal egg count reduction after treatment.
Procedure A farm was selected where the population of small strongyles in horses was known to be resistant to oxibendazole. Horses were allocated to treatment groups based on faecal egg counts. After treatment, faecal samples were taken up to 109 days after treatment and faecal egg counts estimated. Faecal cultures were used to estimate the contribution of small and large strongyles to the faecal egg counts at each sampling.
Results Moxidectin (0.4 mg/kg) suppressed faecal egg counts for 109 days after treatment in most horses compared to 40 days with ivermectin (0.2 mg/kg), 13 days with morantel (9.4 mg/kg) and less than 13 days with oxibendazole (10 mg/kg). Most of the faecal egg count was attributable to small strongyles based on faecal culture, although Strongylus vulgaris was present in some samples in low numbers. Oxibendazole resistance in small strongyles was confirmed and a less than expected efficacy of morantel was also seen.
Conclusion Moxidectin was highly effective in reducing faecal egg counts after treatment for at least 12 weeks and up to 16 weeks in most horses. These horses were infected with a population of small strongyles known to be resistant to oxibendazole and possibly morantel. The duration of the reduction in faecal egg counts after treatment with moxidectin (0.4 mg/kg) was at least twice that of ivermectin (0.2 mg/kg) and greater than four times that for morantel and oxibendazole.     

Prevalence of benzimidazole-resistant small strongyles in horses in a southeastern Pennsylvania practice

A survey was conducted to determine the prevalence of benzimidazole (BZ)-resistant small strongyles in horses in a southeastern Pennsylvania practice. Resistant parasites were found in 291 of 342 horses surveyed. Anthelmintic practices and pasture management factors in use for 3 to 6 years did not correlate with the presence of resistant small strongyles. Benzimidazole-resistant small strongyles were recovered in horses that had been treated alternately with BZ and non-BZ products and in horses receiving BZ products as infrequently as twice a year. However, inasmuch as the horses may have been infected with resistant small strongyles before the various anthelmintic schedules were implemented, it was not possible to attribute BZ-resistance to any particular pattern of drug use. Fifty-one (14.9%) horses had BZ-susceptible small strongyles: these horses were on poor overall parasite control programs and had received BZ products no more than once a year. Benzimidazole-piperazine and non-BZ drugs were effective in herds infected with BZ-resistant small strongyles.     

Epidemiological approach to the control of horse strongyles

An investigation of the spring rise in strongyle egg output of grazing horses on two commercial horse farms in northern USA in 1981 and 1982 revealed two distinct spring and summer rises in faecal egg counts, with peaks in May and August/September. There was a marked rise in the concentration of infective larvae on pasture two to four weeks after the peaks in egg output, so that grazing horses were at serious risk from June onwards and pasture larval counts on one farm did not fall to low levels until June of the following year. The spring and summer rises in faecal egg counts appeared to be seasonal in nature, to be derived largely from worms developing from previously ingested larvae, rather than from newly ingested larvae, and to be unrelated to the date of foaling. An epidemiological approach to strongyle control based on prophylactic treatments in the spring successfully eliminated the spring rise in egg output but was inadequate to control the summer rise or subsequent escalation of pasture infectivity in September. It was, nevertheless, superior to a conventional treatment programme at eight week intervals, using the same drug, pyrantel pamoate. Prophylactic spring/summer treatments proved to be much more effective. Both pyrantel pamoate at four week intervals and ivermectin at eight week intervals kept faecal egg counts at low levels during spring and summer. As few as two ivermectin treatments (11 May, 6 July) resulted in a sixfold reduction in pasture larval counts on 9 November and 3 January for the treated group (8872, 8416 stage three larvae [L3]/kg) compared to the control group (52,824, 50,984 L3/kg).(ABSTRACT TRUNCATED AT 250 WORDS)     

A field evaluation of oxibendazole in horses infected with benzimidazole resistant small strongyles

Horses with a history of frequent benzimidazole (BZD) treatment were used in a trial to assess the effectiveness of oxibendazole (OBZ). Initial investigations established that these animals were infected with small strongyles resistant to thiabendazole (TBZ), mebendazole (MBZ), cambendazole (CBZ), oxfendazole (OXF) and fenbendazole (FBZ).The herd was subsequently divided into four groups and received TBZ, CBZ, OBZ, or no treatment. OBZ effectly reduced fecal egg counts. Similar reductions were not observed with TBZ or CBZ.     

Overview of the use of antimicrobials for the treatment of bacterial infections in horses

Use of antimicrobial drugs is central to the treatment of primary and secondary bacterial infection in horses. When selecting an antimicrobial to treat confirmed or suspected bacterial infection multiple factors should be considered, including: the likely infectious agent; distribution and dosage of selected drugs; mechanisms of action; and potential side effects. Many of these issues will be covered in subsequent articles in this series. The aim of this paper is to aid the clinician in the rational selection of antimicrobials by reviewing the mode of action, spectrum of activity, pharmacokinetics, pharmacodynamics, indications and potential side effects of the main classes of antimicrobial drugs. Extralabel use of drugs is common in veterinary medicine due to a lack of licensed products. This increases the importance of a thorough understanding of antimicrobials and their possible adverse effects.     

Effectiveness of an ivermectin liquid formulation given by nasogastric tube against strongyles in horses

Twenty horses were treated with ivermectin either by nasogastric tube with a liquid formulation for sheep or per os with a paste formulation for horses at a dosage of 200 μg/kg of body weight. Fecal samples were collected from these horses and from ten untreated horses at the time of treatment and every 2 wk thereafter for up to 10 wk. The samples were examined for nematode eggs using the Cornell-McMaster dilution and the Cornell-Wisconsin Double Centrifugation procedures.

There were no signs of toxicosis in horses treated with ivermectin. Strongyle eggs were found in the feces of all horses before treatment. Subsequently, they were found in untreated horses, but not in treated horses at 2 wk nor in most of them for up to 8 wk after treatment. At 10 wk most of these horses had strongyle eggs in their feces, but in general fewer than at pretreatment.

     

Overview of the use of antimicrobial drugs for the treatment of bacterial infections in horses

The use of antimicrobials in veterinary medicine is under great scrutiny with the emergence of antimicrobial resistance in the human population. Equine veterinarians rely on antimicrobials as an essential tool for the treatment of infections in horses, but there is much criticism of some use, particularly prophylaxis. While the appropriate use of antimicrobials can be justified in equine medicine, the misuse cannot. The definition of appropriate use is complex and involves the indication for therapy, antimicrobial selection, dosing regimen and timing and route of administration, duration of therapy and modification of therapy based on microbial susceptibility and clinical response. The aim of this article is to provide guidance on these factors to assist equine veterinarians in determining what constitutes appropriate antimicrobial use in horses.     

The use of age-clustered pooled faecal samples for monitoring worm control in horses

A study was performed on two horse farms to evaluate the use of age-clustered pooled faecal samples for monitoring worm control in horses. In total 109 horses, 57 on farm A and 52 on farm B, were monitored at weekly intervals between 6 and 14 weeks after ivermectin treatment. This was performed through pooled faecal samples of pools of up to 10 horses of the groups 'yearlings' (both farms), '2-year-old' (two pools in farm A), '3-year-old' (farm A) and adult horses (four pools on farm A and five pools on farm B), which were compared with the mean individual faecal egg counts of the same pools. A very high correlation between the faecal egg counts in pooled samples and the mean faecal egg counts was seen and also between the faecal egg counts in pooled samples and larval counts from pooled faecal larval cultures. Faecal egg counts increased more rapidly in yearlings and 2-year-old horses than in older horses. This implied that in these groups of young animals faecal egg counts of more than 200 EPG were reached at or just after the egg reappearance period (ERP) of 8 weeks that is usually indicated for ivermectin. This probably means that, certainly under intensive conditions, repeated treatment at this ERP is warranted in these young animals, with or without monitoring through faecal examination. A different situation is seen in adult animals. Based on the mean faecal egg counts on both farms and on the results of pooled samples in farm A, using 100 EPG as threshold, no justification for treatment was seen throughout the experimental period. However, on farm B values of 100 EPG were seen at 9 and 11, 13 and 14 and 14 weeks after ivermectin treatment in pools 10, 12 and 13, respectively. This coincided with the presence of one or two horses with egg counts above 200 EPG. The conclusion is that random pooled faecal samples of 10 adult horses from a larger herd, starting at the ERP and repeating it at, for instance, 4-week intervals, could be used for decisions on worm control. However, there would be a certain risk for underestimating pasture contamination through missing high-egg excreters. An alternative use of pooled samples would be as a cheap first screening to detect which adult horses really contribute to pasture contamination with worm eggs on a farm. All horses should be sampled and subsequently animals from 'positive' pools can be reexamined individually.     

Anthelmintic treatment in horses: the extra-label use of products and the danger of under-dosing

Anthelmintic products form the basis of helminth control practices on horse stud farms at present. Regular evaluation of the efficacy of these products is advisable, as it will provide information on the worm egg reappearance period and the resistance status in the worm population. The aim of this study was to evaluate the efficacy of doramectin, pyrantel pamoate, ivermectin and moxidectin on a Thoroughbred stud farm in the Western Cape Province, South Africa. The study also compared the anthelmintic efficacy of two moxidectin formulations administered at their recommended dosages (an injectable, at 0.2 mg/kg, not registered for horses, and an oral gel at 0.4 mg/kg, registered for horses). Two mixed-sex groups of 30 yearlings and 40 weaners were tested in 2001 and 2002, respectively, divided into 3 and 4 groups of equal size. In 2001, moxidectin was one of 3 drugs administered orally and at a dose rate of 0.4 mg/kg. In 2002, pyrantel pamoate and ivermectin were orally administered at 19 and 0.2 mg/kg. Moxidectin and doramectin (the latter not registered for horses) were administered by intramuscular injection at a dose of 0.2 mg/kg, the dosage registered for other host species. The faecal egg count reduction test was used to determine the anthelmintic efficacies in both years. Each animal acted as its own control and the arithmetic mean faecal egg count and lower 95% confidence limit was calculated for each of the groups. A 100% reduction in the faecal egg counts and a 100% lower 95% confidence limit was recorded for moxidectin (0.4 mg/kg) in 2001. In 2002, a 99% and 96% reduction was recorded for pyrantel pamoate and ivermectin, respectively. In the same year doramectin and moxidectin (both injectable and given at 0.2 mg/kg) did not have any effect on worm egg counts. Of the 4 drugs tested in 2002, only pyrantel pamoate recorded lower 95% confidence limits above 90%.